• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Serina Therapeutics Inc.

    3/25/26 5:31:25 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SER alert in real time by email
    S-8 1 forms-8.htm S-8

     

    As filed with the Securities and Exchange Commission on March 25, 2026

     

    Registration No. 333-        

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT

    UNDER

    THE SECURITIES ACT OF 1933

     

    SERINA THERAPEUTICS, INC.

    (Exact name of registrant as specified in its charter)

     

    Delaware   82-1436829
    (State of incorporation)   (I.R.S. Employer Identification No.)
         

    601 Genome Way,

    Suite 2001

    Huntsville, Alabama

      35806
    (Address of Principal Executive Offices)   (Zip Code)

     

    Serina Therapeutics, Inc. 2024 Equity Incentive Plan

    (Full title of the plan)

     

    Steve Ledger

    Chief Executive Officer
    Serina Therapeutics, Inc.

    601 Genome Way, Suite 2001

    Huntsville, Alabama 35806

    (Name and address of agent for service)

     

    (256) 327-9630

    (Telephone number, including area code, of agent for service)

     

    Copies to:

    Scott Ludwig

    Stephen Hinton

    Bradley Arant Boult Cummings LLP

    200 Clinton Avenue Huntsville Alabama 35801

    (256) 517-5100

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

     

    Large accelerated filer ☐ Accelerated filer ☐
    Non-accelerated filer ☒ Smaller reporting company ☒
      Emerging growth company ☐

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 is being filed by Serina Therapeutics, Inc. (the “Company”, “we,”, “us,” or “our”) to register 535,478 additional shares of the Company’s common stock (the “common stock”) to a total of 3,210,478 shares of common stock, reserved for issuance under the Company’s 2024 Equity Incentive Plan (the “2024 Plan”) pursuant to the provisions of the 2024 Plan which provides for annual automatic increases in the number of shares of common stock reserved for issuance under the 2024 Plan in an amount equal to 5% of the outstanding shares of common stock on the last day of the immediately preceding fiscal year.

     

    Pursuant to General Instruction E regarding Registration of Additional Securities, the contents of the Registration Statements on Form S-8 filed with the U.S. Securities and Exchange Commission (the “SEC”) on June 17, 2024 (Registration No. 333-280250) and on April 2, 2025 (Registration No. 333-286343) are incorporated by reference herein except as otherwise updated or modified by this filing. All exhibits required by General Instruction E to Form S-8 are filed as exhibits hereto.

     

     

     

     

    PART II

    INFORMATION REQUIRED IN THE REGISTRATION STATEMENT

     

    Item 3. Incorporation of Documents by Reference

     

    We incorporate by reference in this Registration Statement the documents listed below, excluding any portions of such documents that have been “furnished” but not “filed” for purposes of the Securities Exchange Act of 1934, as amended (the “Exchange Act”):

     

    ●our Annual Report on Form 10-K for the year ended December 31, 2025, filed with the SEC on March 25, 2026 (the “Annual Report”);

     

    ●our Definitive Proxy Statement on Schedule 14A, filed with the SEC on September 26, 2025, and our Amendment No. 1 to Definitive Proxy Statement on Schedule 14A, filed with the SEC on October 27, 2025;

     

    ●all other reports filed with the SEC pursuant to Section 13(a) or 15(d) of the Exchange Act since December 31, 2025; and

     

    ●the disclosures set forth under the caption “Description of Capital Stock” in the Company’s Registration Statement on Form S-1 (File No. 333-279121), filed with the SEC on May 3, 2024, and any other amendment or report filed for the purpose of updating such description.

     

    In addition, any future filings made by us with the SEC under Sections 13(a), 13(c), 14, or 15(d) of the Exchange Act, prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed to be incorporated by reference in this Registration Statement and to be part hereof from the date of filing of such documents; provided, however, that documents or information deemed to have been furnished and not filed in accordance with SEC rules shall not be deemed incorporated by reference into this Registration Statement.

     

    Any statement contained in a document incorporated or deemed to be incorporated by reference in or deemed to be part of this Registration Statement shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in this Registration Statement or in any subsequently filed document that also is or is deemed to be incorporated by reference in this Registration Statement modifies or supersedes that statement. Any statement contained in a document that is deemed to be incorporated by reference or deemed to be part of this Registration Statement after the most recent effective date may modify or replace existing statements contained in this Registration Statement. Any such statement so modified or replaced shall not be deemed, except as so modified or replaced, to constitute a part of this Registration Statement.

     

     

     

     

    Item 8. Exhibits

     

    Exhibit No.   Description of Exhibit
         
    5.1 *   Opinion of Bradley Arant Boult Cummings LLP as to the validity of the securities being registered.
    10.1  Serina Therapeutics Inc. 2024 Equity Incentive Plan, as amended (incorporated by reference to Exhibit 10.1 to the Company’s Current Report on Form 8-K filed with the SEC on December 18, 2024).
    23.1 *   Consent of Frazier & Deeter, LLC.
    23.2  Consent of Counsel (included in Exhibit 5.1).
    24.1  Power of Attorney (contained on the signature page hereto).
    107  Filing Fee Table

     

    * Filed herewith

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, the registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized in the City of San Jose, State of California, on March 25, 2026.

     

     SERINA THERAPEUTICS, INC.
       
     By:/s/ Steve Ledger
     Name:Steve Ledger
     Its:Chief Executive Officer

     

     

     

     

    POWER OF ATTORNEY

     

    KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Steve Ledger and Gregory S. Curhan, and each of them, his or her true and lawful attorneys-in-fact and agents with full powers of substitution and resubstitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign this Registration Statement on Form S-8 with any completions, additions, deletions or other changes that Mr. Ledger or Mr. Curhan shall deem necessary, appropriate or advisable, to sign any or all amendments to this Registration Statement on Form S-8, including post-effective amendments, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in and about the premises, as fully to all intents and purposes as he or she might or could do in person, and hereby ratifies and confirms all his or her said attorneys-in-fact and agents, or any of them, or his or her substitute or substitutes may lawfully do or cause to be done by virtue thereof.

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this registration statement has been signed by the following persons in the capacities and on the dates indicated.

     

    Signature   Title   Date
    /s/ Balkrishan (Simba) Gill   Executive Chairman of the Board of Directors   March 25, 2026
    Balkrishan (Simba) Gill, Ph.D        
             
    /s/ Steve Ledger   Chief Executive Officer and Director   March 25, 2026
    Steve Ledger    (Principal Executive Officer)    
             
    /s/ Gregory S. Curhan   Chief Financial Officer   March 25, 2026
    Gregory S. Curhan    (Principal Financial and Accounting Officer)    
             
    /s/ Gregory H. Bailey   Director   March 25, 2026
    Gregory H. Bailey, M.D.        
             
    /s/ Stephen Brannan   Director   March 25, 2026
    Stephen Brannan, M.D.        
             
    /s/ Richard Marshall   Director   March 25, 2026
    Richard Marshall, CBE, M.D., Ph.D.        
             
    /s/ Jay Venkatesan   Director   March 25, 2026
    Jay Venkatesan, M.D.        
             
    /s/ Karen J. Wilson   Director   March 25, 2026
    Karen J. Wilson        

     

     

     

    Get the next $SER alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $SER

    DatePrice TargetRatingAnalyst
    7/14/2025$15.00Buy
    H.C. Wainwright
    More analyst ratings

    $SER
    SEC Filings

    View All

    Amendment: SEC Form 10-K/A filed by Serina Therapeutics Inc.

    10-K/A - Serina Therapeutics, Inc. (0001708599) (Filer)

    3/27/26 1:57:29 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Serina Therapeutics Inc.

    S-8 - Serina Therapeutics, Inc. (0001708599) (Filer)

    3/25/26 5:31:25 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Serina Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - Serina Therapeutics, Inc. (0001708599) (Filer)

    3/25/26 4:08:38 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SER
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Bailey Gregory bought $17,745 worth of shares (3,866 units at $4.59), increasing direct ownership by 6% to 67,243 units (SEC Form 4)

    4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

    12/19/24 4:05:12 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bailey Gregory bought $6,851 worth of shares (1,137 units at $6.03), increasing direct ownership by 2% to 63,377 units (SEC Form 4)

    4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

    9/24/24 4:30:06 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bailey Gregory bought $88,257 worth of shares (14,388 units at $6.13), increasing direct ownership by 30% to 62,240 units (SEC Form 4)

    4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

    9/20/24 6:59:29 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SER
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    $SER
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    $SER
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights

    - FDA Grants IND Clearance for SER-252- SER-252 Phase 1b Trial Initiated- Closed Private Placement Financing of up to $30 Million HUNTSVILLE, March 25, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today reported its financial results for the full year ended December 31, 2025 and provided recent business highlights. "This past year was defined by execution, advancing SER-252 from IND filing through FDA clearance, into the clinic while strengthening our balance sheet to support the clinical milestones ahead," said Steve Ledger, CEO of S

    3/25/26 4:20:00 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Serina Therapeutics to Present at the 38th Annual Roth Conference

    HUNTSVILLE, AL, March 24, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, announced that Steve Ledger, Chief Executive Officer, will present in a fireside chat at the 38th Annual Roth Conference in Dana Point, CA on March 24, 2026, at 11:30 a.m. PST. A live webcast of the fireside chat style presentation will be accessible to registered attendees at this link. An archived replay will be available on-demand for 90 days following the event. About Serina Therapeutics Serina is a clinical-stage biotechnology company developing a pipeline of wholly owned dru

    3/24/26 6:00:00 AM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson's Disease

    - First tranche of $15 million expected to close on March 20, 2026; second tranche of up to $15 million available, for up to $30 million in total proceeds from the sale of common stock and pre-funded warrants priced at $2.25 per share, representing a 68% premium to the March 17, 2026 closing price– - Financing includes 50% warrant coverage priced at $5 per share, representing a 273% premium to market, if exercised would raise up to an additional $33.3 million, extending runway into 2H 2027 - - Proceeds to support ongoing single-ascending dose (SAD) registrational study arm under 505(b)(2) NDA pathway – HUNTSVILLE, AL, March 18, 2026 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina

    3/18/26 4:10:00 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Moreadith Randall

    4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

    3/24/26 7:24:24 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Moreadith Randall

    4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

    3/20/26 2:20:45 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 4 filed by Chief Scientific Officer Moreadith Randall

    4 - Serina Therapeutics, Inc. (0001708599) (Issuer)

    2/17/26 8:35:57 AM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    H.C. Wainwright initiated coverage on Serina Therapeutics with a new price target

    H.C. Wainwright initiated coverage of Serina Therapeutics with a rating of Buy and set a new price target of $15.00

    7/14/25 8:54:25 AM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SER
    Leadership Updates

    Live Leadership Updates

    View All

    Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry

    HUNTSVILLE, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE:SER), a clinical-stage biotechnology company advancing its lead Investigational New Drug ("IND") candidate, SER-252, for advanced Parkinson's disease, enabled by its proprietary POZ PlatformTM drug optimization technology, today announced the appointment of Joshua Thomas, Ph.D., as Vice President and Head of Chemistry. He will oversee internal and external chemistry efforts to optimize POZ-based candidates, supporting efficient translation from discovery through development. Prior to joining Serina, Dr. Thomas served in progressive scientific leadership roles at Mersana Therapeutics,

    12/11/25 4:15:00 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Serina Therapeutics Appoints Stephen Brannan, M.D. to Board of Directors

    - Renowned neuroscience drug developer joins to support strategic development of long-acting CNS therapeutics – HUNTSVILLE, AL, May 22, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing a pipeline of product candidates leveraging its proprietary POZ Platform™ drug optimization technology, today announced the appointment of Stephen (Steve) Brannan, M.D., to its Board of Directors. Dr. Brannan brings more than three decades of experience in neuroscience and neuropsychiatry drug development, with a proven track record of leading clinical programs from early development through regulatory approval and commercialization

    5/22/25 4:50:00 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Serina Therapeutics Appoints Dr. Jay Venkatesan to its Board of Directors

    HUNTSVILLE, AL, Feb. 12, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company developing its proprietary POZ Platform™ drug optimization technology, today announced the appointment of Jay Venkatesan, MD, MBA, to its Board of Directors. Dr. Venkatesan brings deep expertise in biotechnology investment, company building, and strategic growth, having successfully led and advised multiple biopharma companies through pivotal stages of development, including high-profile mergers and acquisitions. Dr. Venkatesan most recently served as Chairman, President, and CEO of Angion Biomedica until its merger with Elicio Therapeutics in 2023. He

    2/12/25 4:15:00 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SER
    Financials

    Live finance-specific insights

    View All

    Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights

    HUNTSVILLE, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina" or the "Company") (NYSE:SER), a clinical-stage biotechnology company advancing its lead Investigational New Drug ("IND") candidate, SER-252, for advanced Parkinson's disease, enabled by its proprietary POZ Platform™ drug optimization technology, today announced its financial results for the third quarter ended September 30, 2025, along with key recent updates. Steve Ledger, Chief Executive Officer of Serina, stated, "The FDA's alignment with our plan to advance SER-252 under a 505(b)(2) NDA pathway, and its recognition of the Phase 1b trial as registrational, represents a key milestone for Serina. This outco

    11/13/25 6:10:00 AM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights

    HUNTSVILLE, Aug. 11, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company advancing its lead IND candidate, SER-252, for advanced Parkinson's disease, enabled by its proprietary POZ Platform™ drug optimization technology, today announced its financial results for the second quarter ended June 30, 2025, along with key recent updates. "We're proud of the momentum we've built across our development programs. With SER-252 on track to enter the clinic later this year and the recent advancement of SER-270 for tardive dyskinesia, we are demonstrating how the POZ Platform can enable differentiated, long-acting therapies across neurologic

    8/11/25 4:30:00 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Serina Therapeutics Announces Date for 2025 Annual Stockholders Meeting

    HUNTSVILLE, July 01, 2025 (GLOBE NEWSWIRE) -- Serina Therapeutics, Inc. ("Serina") (NYSE:SER), a clinical-stage biotechnology company, today announced that its Board of Directors has established November 7, 2025, as the date of its 2025 annual meeting of stockholders (the "Annual Meeting"). The time and location of the Annual Meeting will be set forth in the Serina's definitive proxy statement for the Annual Meeting to be filed with the Securities and Exchange Commission (the "SEC"). Because the date of the Annual Meeting represents a change of more than 30 days from the anniversary of Serina's 2024 annual meeting of stockholders, the deadline for stockholder proposals to be submitted pur

    7/1/25 4:15:00 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $SER
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by Serina Therapeutics Inc.

    SC 13D/A - Serina Therapeutics, Inc. (0001708599) (Subject)

    12/9/24 4:45:59 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Serina Therapeutics Inc.

    SC 13G/A - Serina Therapeutics, Inc. (0001708599) (Subject)

    11/14/24 5:09:38 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Serina Therapeutics Inc.

    SC 13D/A - Serina Therapeutics, Inc. (0001708599) (Subject)

    7/5/24 4:01:13 PM ET
    $SER
    Biotechnology: Pharmaceutical Preparations
    Health Care